Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis,[1] under development by Anthos Therapeutics.

The hope behind its developoment is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding.

[1] It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke.

[2] Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban.

You can help Wikipedia by expanding it.This drug article relating to the blood and blood forming organs is a stub.